Insider Sell: BioMarin Pharmaceutical
1:32PM ET 5/04/2022 MT NewswiresGeorge Eric Davis, Executive Vice President, Chief Legal Officer, on April 29, 2022, sold 15,347 shares in BioMarin Pharmaceutical (BMRN) for $1,233,592....
Insider Sell: BioMarin Pharmaceutical
1:30PM ET 5/04/2022 MT NewswiresRichard A Meier, Director, on May 02, 2022, sold 3,878 shares in BioMarin Pharmaceutical (BMRN) for $318,345. Following the Form 4 filing with the SEC,...
Insider Sell: BioMarin Pharmaceutical
9:53AM ET 5/03/2022 MT NewswiresJean Jacques Bienaime, Director, Chief Executive Officer, on April 28, 2022, sold 25,000 shares in BioMarin Pharmaceutical (BMRN) for $2,085,550. Following...
--Oppenheimer Adjusts BioMarin Pharmaceutical Price Target to $94 From $95, Maintains Perform Rating
11:22AM ET 4/28/2022 MT Newswires(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
Research Alert: CFRA Keeps Buy Opinion On Shares Of Biomarin Pharmaceutical
10:55AM ET 4/28/2022 MT NewswiresCFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as...
Wedbush Adjusts Price Target on BioMarin Pharmaceutical to $147 From $155 on Increased Share Count, Keeps Outperform Rating
6:50AM ET 4/28/2022 MT NewswiresBioMarin Pharmaceutical (BMRN) has an average rating of outperform and price targets ranging from $90 to $168, according to analysts polled by Capital IQ....
BioMarin Pharmaceutical Q1 EPS, Revenue Rise; Maintains 2022 Guidance
4:19PM ET 4/27/2022 MT NewswiresBioMarin Pharmaceutical (BMRN) on Wednesday reported Q1 earnings of $0.63 per diluted share, up from $0.09 a year ago. Analysts polled by Capital IQ...
-- Earnings Flash (BMRN) BIOMARIN PHARMACEUTICAL Posts Q1 Revenue $519.4M
4:10PM ET 4/27/2022 MT Newswires...
Earnings Reaction History: Biomarin Pharmaceutical, 33.3% Follow-Through Indicator, 3.3% Sensitive
1:20PM ET 4/27/2022 MT NewswiresExpected Earnings Release: 04/27/2022, After-hours Avg. Extended-Hours Dollar Volume: $15,979,656 Biomarin Pharmaceutical (BMRN) is due to issue its...
Morgan Stanley Lifts BioMarin Pharmaceutical to Overweight From Equalweight, Price Target to $113 From $96
6:24AM ET 4/25/2022 MT NewswiresBioMarin Pharmaceutical (BMRN) has an average rating of outperform and price targets ranging from $90 to $168, according to analysts polled by Capital IQ....